Almac Announce Launch of Bioinformatics ConsultancyBy Almac, PRNE
Wednesday, February 16, 2011
Almac Your Bioinformatics Partner
CRAIGAVON, Northern Ireland, February 17, 2011 - Almac's Diagnostics business unit today announced the launch of its
Bioinformatics Consultancy service.
Almac's Bioinformatics Consultancy supports discovery and development of
biomarkers as well as enabling an in-depth understanding of biology by
partnering with customers in the pharmaceutical, biotech and diagnostics
setting, from the initial study design through to the interpretation of data
The consultancy service offers a range of customisable bioinformatics and
biostatistics solutions which include: Biomarker Discovery and Development,
Exploratory Analysis, Mechanistic and Functional Analysis, Traditional and
Next Generation Sequencing Data Analysis, Biostatistics and Data Integration.
The solutions are delivered through a large and experienced
bioinformatics team from a wide range of disciplines including biology,
medicine, mathematics and biostatistics. In addition to the team's expertise
in bioinformatics and biostatistics they also have substantial experience in
molecular and cell biology, drug discovery and development, and diagnostic
Professor Paul Harkin, President and Managing Director of Almac's
Diagnostic business unit said: "Bioinformatics has always been a key strength
for us at Almac, over the years we have built-up a world class team of
bioinformaticians and biostatisticians. This team has provided invaluable
support for both our internal research and our external work. And, the launch
of the full bioinformatics consultancy business is the next logical step in
enabling our customer's to access this important resource".
Almac has secured its position in the personalised medicine market,
following collaborations with some of the top Pharma companies worldwide
including Pfizer, Eli Lilly and Merck.
Almac's Diagnostic business unit is focused on the discovery
and development of biomarkers. It utilises its proprietary technology,
extensive experience and expertise to offer solutions to biotech and Pharma
partners. Almac focus on providing a range of services including exploratory
biomarker discovery studies, verification studies for existing markers, assay
development and biomarker validation.
The Almac Group offers a broad range of services from R&D, biomarker
discovery and development, API manufacture, formulation development, clinical
trial supply and IXRS technology (IVRS/IWRS), to commercial-scale
manufacture. Almac provides services to more than 600 companies, including
all the world leaders in the pharmaceutical and biotech sectors.
The company employs almost 3,000 individuals and is headquartered in
Craigavon, Northern Ireland. US operations are based in Pennsylvania, North
Carolina and California. Staff have now transferred to Almac's new $120m
North American Headquarters which is now fully operational.
For more information about the Almac Group, please visit
Contact: Emma O'Neill, Almac, +44(0)28-38-33-7575, Emma.oneill at almacgroup.com; Tristan Jervis, DeFacto, T.Jervis at Defacto.com, Tel: +44-2078-613019; e-mail info at almacgroup.com
Tags: Almac, Craigavon, February 17, ireland, Northern Ireland, United Kingdom